Literature DB >> 19143531

Effects of omeprazole on plasma levels of raltegravir.

Marian Iwamoto1, Larissa A Wenning, Bach-Yen Nguyen, Hedy Teppler, Allison R Moreau, Rand R Rhodes, William D Hanley, Bo Jin, Charlotte M Harvey, Sheila A Breidinger, Neal Azrolan, H Frank Farmer, Robin D Isaacs, Jeffery A Chodakewitz, Julie A Stone, John A Wagner.   

Abstract

Raltegravir, a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has pH-dependent solubility. Raltegravir plasma concentration increases with omeprazole coadministration in healthy subjects; this is likely secondary to an increase in bioavailability attributable to increased gastric pH. Increased gastric pH has been reported in HIV-1-infected individuals, and the effects of omeprazole in this intended population may be diminished. Further investigation is necessary.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19143531     DOI： 10.1086/596503

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  23 in total

1.  Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.

Authors:  Jennifer J Kiser; J Brock Bumpass; Amie L Meditz; Peter L Anderson; Lane Bushman; Michelle Ray; Julie A Predhomme; Joseph Rower; Sam Mawhinney; Richard Brundage
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

Review 2.  Drug interactions and antiretroviral drug monitoring.

Authors:  Matthew Foy; C John Sperati; Gregory M Lucas; Michelle M Estrella
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

Review 3.  A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Authors:  R Douglas Bruce; David E Moody; Frederick L Altice; Marc N Gourevitch; Gerald H Friedland
Journal:  Expert Rev Clin Pharmacol       Date:  2013-05       Impact factor: 5.045

4.  Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study).

Authors:  Cyril Clavel; Gilles Peytavin; Roland Tubiana; Cathia Soulié; Catherine Crenn-Hebert; Isabelle Heard; François Bissuel; Houria Ichou; Claudia Ferreira; Christine Katlama; Anne-Geneviève Marcelin; Laurent Mandelbrot
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

5.  Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection.

Authors:  Uriel Sandkovsky; Susan Swindells; Ryan Moore; Edward P Acosta; Courtney V Fletcher
Journal:  Pharmacotherapy       Date:  2012-02       Impact factor: 4.705

6.  Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers.

Authors:  Lingzhi Wang; Gaik Hong Soon; Kok-Yong Seng; Jun Li; Edmund Lee; Eu-Leong Yong; Boon-Cher Goh; Charles Flexner; Lawrence Lee
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

7.  Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling.

Authors:  Xiaomei I Liu; Jeremiah D Momper; Natella Y Rakhmanina; Dionna J Green; Gilbert J Burckart; Tim R Cressey; Mark Mirochnick; Brookie M Best; John N van den Anker; André Dallmann
Journal:  Clin Pharmacokinet       Date:  2020-11       Impact factor: 6.447

8.  Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine.

Authors:  Amit Khatri; Sandeep Dutta; Martin Dunbar; Thomas Podsadecki; Roger Trinh; Walid Awni; Rajeev Menon
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

9.  Raltegravir: The evidence of its therapeutic value in HIV-1 infection.

Authors:  Kavya Ramkumar; Nouri Neamati
Journal:  Core Evid       Date:  2010-06-15

Review 10.  Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients.

Authors:  Jamie D Croxtall; Susan J Keam
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.